EPH and Ephrins in Pathogenesis and as Drug Target
Deadline for manuscript submissions: closed (23 December 2023) | Viewed by 4982
Interests: drug discovery; Eph; ephrin; protein–protein interaction inhibitors (PPI-is); polyphenols; cancer; platelets
Special Issues, Collections and Topics in MDPI journals
Interests: Eph; ephrin; hypertension; heart rhythm; diabetes; ubiquitin ligase; RNA polymerase II; neural tube defects
Thirty-five years after the discovery of the first EPH gene by Takaku’s group, Eph receptors and the ephrin ligands are known to constitute a complex and redundant cellular communication network that is mainly involved in adhesion/repulsion responses; these are key processes during embryogenesis, angiogenesis, in the organized cell renewal of the epithelial tissues and in the regeneration/remodeling after injuries. Therefore, it is not surprising that members of this system were shown to be involved in many pathophysiological conditions such as inflammation and atherosclerosis, neurological disorders and cancer, making Eph receptors and ephrin ligands new attractive targets for pharmacologists and pharmaceutical chemists.
At present a plethora of biological techniques and pharmacological tools are available to investigate the roles and the potential benefits of Eph/ephrin targeting in several diseases. Small molecules, peptides and antibodies have shown promising and convincing results in vitro and in preclinical animal models, and some of them have reached clinical trials. Unfortunately, despite these research efforts, drugs targeting this system have not yet reached the market, and the gap between bench and bed still exists.
Taking advantage of the third congress on the Eph/ephrin system (www.ephrins.org), which we recently organized in Montreal after four years of absence due to the pandemic, the present Special Issue of Pharmaceuticals aims to be not only a synthesis of this meeting, but also an opportunity for all scientists in this field. This Special Issue aims to collect the most updated works and to be a valid source of inspiration for future research in the field of Eph/ephrin targeting.
We sincerely hope that you will be able to submit your original contributions to this Special Issue, which aims to be a valuable collection of state-of-the-art works on the Eph/ephrin targeting puzzle.
Dr. Massimiliano Tognolini
Prof. Dr. Jiangping Wu
Dr. Carmine Giorgio
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- drug discovery
- PPI inhibitors
- small molecules